Cirrhosis from hepatitis C (HCV) is now the most common indication for liver transplant (LT) in the U.S., but between 2004 and 2013, new LT listings for NASH increased by 170%. Unfortunately, fibrosis progression leading to cirrhosis, liver cancer, and liver decompensation continues to occur after transplantation. Once cirrhosis and decompensation are evident, patient survival is poor and repeat LT is considered to improve outcomes. Therefore, the never-ending thirst for new approaches in the management of patients pre- and post-transplant has led to a very promising future in transplantation, thought there is much to learn to achieve better patient outcomes. This issue of Clinics in Liver Disease addresses the core areas to achieve better patient outcomes, with articles devoted to coagulopathy before liver transplant, challenges in renal failure before LT, LT for acute alcoholic hepatitis, LT in the pregnant patient, bariatric surgery and LT,and MELD Scores in prioritization of LT, to name a few. Readers will place a high value on the current state of liver transplantation in this issue.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Erratum - p. xiii 8. Preface - p. xv 9. Liver Transplantation and Bariatric Surgery: Best Approach - p. 215 10. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma - p. 231 11. Coagulopathy Before and After Liver Transplantation: From the Hepatic to the Systemic Circulatory Systems - p. 253 12. Model for End-Stage Liver Disease–Sodium Score: The Evolution in the Prioritization of Liver Transplantation - p. 275 13. Extended Criteria Donors in Liver Transplantation - p. 289 14. Challenges in Renal Failure Treatment Before Liver Transplant - p. 303 15. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation - p. 321 16. Management of Immunosuppression in Liver Transplantation - p. 337 17. Liver Transplantation in Alpha-1 Antitrypsin Deficiency - p. 355 18. Predictors of Cardiovascular Events After Liver Transplantation - p. 367 19. Autoimmune Hepatitis in the Liver Transplant Graft - p. 381 20. Cholestatic Liver Diseases After Liver Transplant - p. 403 21. The New Era of Hepatitis C: Therapy in Liver Transplant Recipients - p. 421 22. Liver Retransplantation: How Much Is Too Much? - p. 435
No hay muestra disponible
No hay ficha técnica disponible
Cirrhosis from hepatitis C (HCV) is now the most common indication for liver transplant (LT) in the U.S., but between 2004 and 2013, new LT listings for NASH increased by 170%. Unfortunately, fibrosis progression leading to cirrhosis, liver cancer, and liver decompensation continues to occur after transplantation. Once cirrhosis and decompensation are evident, patient survival is poor and repeat LT is considered to improve outcomes. Therefore, the never-ending thirst for new approaches in the management of patients pre- and post-transplant has led to a very promising future in transplantation, thought there is much to learn to achieve better patient outcomes. This issue of Clinics in Liver Disease addresses the core areas to achieve better patient outcomes, with articles devoted to coagulopathy before liver transplant, challenges in renal failure before LT, LT for acute alcoholic hepatitis, LT in the pregnant patient, bariatric surgery and LT,and MELD Scores in prioritization of LT, to name a few. Readers will place a high value on the current state of liver transplantation in this issue.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Erratum - p. xiii 8. Preface - p. xv 9. Liver Transplantation and Bariatric Surgery: Best Approach - p. 215 10. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma - p. 231 11. Coagulopathy Before and After Liver Transplantation: From the Hepatic to the Systemic Circulatory Systems - p. 253 12. Model for End-Stage Liver Disease–Sodium Score: The Evolution in the Prioritization of Liver Transplantation - p. 275 13. Extended Criteria Donors in Liver Transplantation - p. 289 14. Challenges in Renal Failure Treatment Before Liver Transplant - p. 303 15. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation - p. 321 16. Management of Immunosuppression in Liver Transplantation - p. 337 17. Liver Transplantation in Alpha-1 Antitrypsin Deficiency - p. 355 18. Predictors of Cardiovascular Events After Liver Transplantation - p. 367 19. Autoimmune Hepatitis in the Liver Transplant Graft - p. 381 20. Cholestatic Liver Diseases After Liver Transplant - p. 403 21. The New Era of Hepatitis C: Therapy in Liver Transplant Recipients - p. 421 22. Liver Retransplantation: How Much Is Too Much? - p. 435
No hay muestra disponible
No hay ficha técnica disponible
